FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801418858> ?p ?o ?g. }

• W2801418858 endingPage "2747" @default.
• W2801418858 startingPage "2740" @default.
• W2801418858 abstract "Dasatinib is a potent BCR-ABL1 and Src family tyrosine kinase inhibitor. It is approved at a dose of 100 mg orally daily for the treatment of chronic myeloid leukemia in chronic phase (CML-CP). This dose schedule is associated with myelosuppression and pleural effusions. Anecdotal data suggest that lower doses may be as effective and less toxic. The aim of this study was to assess the efficacy and safety of a lower dose of dasatinib (50 mg daily) in patients with newly diagnosed CML-CP.Seventy-five patients with newly diagnosed CML-CP received dasatinib 50 mg daily. The eligibility and response criteria were standards used in previous protocols.At a median follow-up of 9 months, 60 patients were evaluable for a response at 3 months. The rates of patients achieving BCR-ABL1 transcript levels ≤ 10% and ≤ 1% at 3 months by the International Standard were 93% and 72%, respectively. The rates of complete cytogenetic response by conventional cytogenetics or fluorescence in situ hybridization at 6 and 12 months were 86% and 88%, respectively. At 12 months, 79%, 71%, and 46% of the patients had achieved a major molecular response, a molecular response with a 4.0-log reduction, and a molecular response with a 4.5-log reduction, respectively. Nine patients had a dose interruption for ≤14 days. Only 1 patient developed a pleural effusion requiring a dose reduction to 20 mg. All patients remained alive and with no transformation so far.Dasatinib 50 mg daily is active and well tolerated in patients with newly diagnosed CML-CP. It should be further explored as a new potential standard-of-care option for chronic myeloid leukemia. Cancer 2018;124:2740-2747. © 2018 American Cancer Society." @default.
• W2801418858 created "2018-05-17" @default.
• W2801418858 creator A5013173470 @default.
• W2801418858 creator A5015140142 @default.
• W2801418858 creator A5021380291 @default.
• W2801418858 creator A5028845635 @default.
• W2801418858 creator A5029187559 @default.
• W2801418858 creator A5035293305 @default.
• W2801418858 creator A5049385583 @default.
• W2801418858 creator A5050041791 @default.
• W2801418858 creator A5051949215 @default.
• W2801418858 creator A5055045706 @default.
• W2801418858 creator A5058755419 @default.
• W2801418858 creator A5070065917 @default.
• W2801418858 creator A5080883357 @default.
• W2801418858 creator A5083793750 @default.
• W2801418858 creator A5084290698 @default.
• W2801418858 creator A5088307376 @default.
• W2801418858 creator A5090435894 @default.
• W2801418858 date "2018-05-03" @default.
• W2801418858 modified "2023-10-06" @default.
• W2801418858 title "Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia" @default.
• W2801418858 cites W1968747503 @default.
• W2801418858 cites W1994309500 @default.
• W2801418858 cites W2003973314 @default.
• W2801418858 cites W2058216377 @default.
• W2801418858 cites W2085342571 @default.
• W2801418858 cites W2092606584 @default.
• W2801418858 cites W2097799776 @default.
• W2801418858 cites W2097946794 @default.
• W2801418858 cites W2101635775 @default.
• W2801418858 cites W2130804859 @default.
• W2801418858 cites W2143939343 @default.
• W2801418858 cites W2146658081 @default.
• W2801418858 cites W2160693099 @default.
• W2801418858 cites W2168633862 @default.
• W2801418858 cites W2260921597 @default.
• W2801418858 cites W2397234997 @default.
• W2801418858 cites W2406641958 @default.
• W2801418858 cites W2516246505 @default.
• W2801418858 cites W2592060299 @default.
• W2801418858 cites W2599933225 @default.
• W2801418858 cites W2604610401 @default.
• W2801418858 cites W2612143330 @default.
• W2801418858 cites W2766187515 @default.
• W2801418858 cites W2890138379 @default.
• W2801418858 doi "https://doi.org/10.1002/cncr.31357" @default.
• W2801418858 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6388399" @default.
• W2801418858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29723397" @default.
• W2801418858 hasPublicationYear "2018" @default.
• W2801418858 type Work @default.
• W2801418858 sameAs 2801418858 @default.
• W2801418858 citedByCount "58" @default.
• W2801418858 countsByYear W28014188582018 @default.
• W2801418858 countsByYear W28014188582019 @default.
• W2801418858 countsByYear W28014188582020 @default.
• W2801418858 countsByYear W28014188582021 @default.
• W2801418858 countsByYear W28014188582022 @default.
• W2801418858 countsByYear W28014188582023 @default.
• W2801418858 crossrefType "journal-article" @default.
• W2801418858 hasAuthorship W2801418858A5013173470 @default.
• W2801418858 hasAuthorship W2801418858A5015140142 @default.
• W2801418858 hasAuthorship W2801418858A5021380291 @default.
• W2801418858 hasAuthorship W2801418858A5028845635 @default.
• W2801418858 hasAuthorship W2801418858A5029187559 @default.
• W2801418858 hasAuthorship W2801418858A5035293305 @default.
• W2801418858 hasAuthorship W2801418858A5049385583 @default.
• W2801418858 hasAuthorship W2801418858A5050041791 @default.
• W2801418858 hasAuthorship W2801418858A5051949215 @default.
• W2801418858 hasAuthorship W2801418858A5055045706 @default.
• W2801418858 hasAuthorship W2801418858A5058755419 @default.
• W2801418858 hasAuthorship W2801418858A5070065917 @default.
• W2801418858 hasAuthorship W2801418858A5080883357 @default.
• W2801418858 hasAuthorship W2801418858A5083793750 @default.
• W2801418858 hasAuthorship W2801418858A5084290698 @default.
• W2801418858 hasAuthorship W2801418858A5088307376 @default.
• W2801418858 hasAuthorship W2801418858A5090435894 @default.
• W2801418858 hasBestOaLocation W28014188581 @default.
• W2801418858 hasConcept C104317684 @default.
• W2801418858 hasConcept C121608353 @default.
• W2801418858 hasConcept C126322002 @default.
• W2801418858 hasConcept C138626823 @default.
• W2801418858 hasConcept C141071460 @default.
• W2801418858 hasConcept C143998085 @default.
• W2801418858 hasConcept C185592680 @default.
• W2801418858 hasConcept C2777583451 @default.
• W2801418858 hasConcept C2778729363 @default.
• W2801418858 hasConcept C2778820342 @default.
• W2801418858 hasConcept C2778904597 @default.
• W2801418858 hasConcept C2779536868 @default.
• W2801418858 hasConcept C2779634585 @default.
• W2801418858 hasConcept C55493867 @default.
• W2801418858 hasConcept C71924100 @default.
• W2801418858 hasConcept C90924648 @default.
• W2801418858 hasConceptScore W2801418858C104317684 @default.
• W2801418858 hasConceptScore W2801418858C121608353 @default.
• W2801418858 hasConceptScore W2801418858C126322002 @default.
• W2801418858 hasConceptScore W2801418858C138626823 @default.

• next